刘海美

【摘 要】目的：研究分析曲妥珠单抗联合多西他赛治疗HER2阳性的转移性乳腺癌的临床效果。方法：将2017年4月至2018年4月于本院收治的76例HER2阳性的转移性乳腺癌患者作为此次研究对象，以随机分组的形式将其分为两组，单一组38例患者予以多西他赛化疗方案，联合组38例患者予以曲妥珠单抗联合多西他赛化疗方案，治疗后对比两组患者治疗总有效率、不良反应发生率与炎症性因子水平。结果：1）联合组患者治疗总有效率94.7%高于单一组患者治疗总有效率78.9%，数据差异显著（P<0.05）。2）联合组患者不良反应发生率18.5%低于单一组患者不良反应发生率39.4%，数据差异显著（P<0.05）。3）联合组患者TNF-α、IL-1β、IL-6、IL-8炎性因子水平指标均低于单一组患者，数据差异显著（P<0.05）。结论：曲妥珠单抗联合多西他赛治疗HER2阳性的转移性乳腺癌的临床效果较为理想，且具有较高的安全性，降低了患者炎症性因子水平，治疗效果得到了临床与患者的认可。

【关键词】曲妥珠单抗;多西他赛;HER2阳性;转移性乳腺癌

Therapeutic effect of tritozumab combined with docetaxel on HER2 positive metastatic breast cancer

Liu Haimei

Medical Insurance Office of Heze Municipal Hospital of Shandong Province， Heze， Shandong 274000

[Abstract] Objective：The clinical effect of tritozumab combined with docetaxel in the treatment of HER2 positive metastatic breast cancer was analyzed.Methods：From April 2017 to April 2018， 76 patients with HER2 positive metastatic breast cancer were randomly divided into two groups. One group of 38 patients received docetaxel chemotherapy. 38 patients in the combined group were treated with tritozumab combined with docetaxel. After treatment， the total effective rate， the incidence of adverse reactions and the level of inflammatory factors were compared between the two groups.Results：1）The total effective rate of the combined group was 94.7%， which was significantly higher than that of the single group （78.9%，P<0.05）.2）The incidence of adverse reactions in the combined group （18.5%） was significantly lower than that in the single group （39.4%） （P<0.05）.3）The levels of TNF- α， IL-1 β and IL-6，IL-8 in the combined group were significantly lower than those in the single group （P<0.05）.Conclusion：The clinical effect of tratozumab combined with docetaxel in the treatment of HER2 positive metastatic breast cancer is ideal and has high safety， which reduces the level of inflammatory factors in patients.

[Key words]Trotozumab; Docetaxel; HER2 positive; Metastatic breast cancer

在女性人群中乳腺癌是常見且多发的一种恶性肿瘤疾病，经临床数据研究显示乳腺癌的发病率呈逐年上升的趋势[1]。目前我国呈老龄化的发展趋势，老年乳腺癌的疾病发展过程与中青年比较较慢，侵袭性也低，雌激素受体阳性率所占比例比较高，然而仍有一部分患者发生转移的症状，尤其是HER-2阳性，转移性乳腺癌的预后效果比较差，临床在对其治疗时以化疗为主，但是因患者年龄比较大，机体耐受度极差，因此选择有效性好、安全性高的治疗方案有着重要的意义。此次研究针对曲妥珠单抗联合多西他赛联合治疗HER2阳性的转移性乳腺癌的临床效果进行对比分析，以下为详情数据报告。

1 资料与方法

1.1 研究资料

将2017年4月至2018年4月于本院收治的76例HER2阳性的转移性乳腺癌患者作为此次研究对象，以随机分组的形式将其分为单一组与联合组。……